LENZ Therapeutics Archives

Developments

LENZ Therapeutics, Graphite Bio in merger accord

Closely-held LENZ Therapeutics and Graphite Bio (NASDAQ:GRPH) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company, which will focus on advancing LENZ’...

November 15, 2023

Developments

LENZ partner cleared for Phase 3 presbyopia trial in China

LENZ Therapeutics’ China partner, Ji Xing Pharmaceuticals, was cleared by the Center for Drug Evaluation of the National Medical Products Administration of the PRC to conduct a Phase 3 clinical trial of LNZ100...

August 7, 2023

Developments

LENZ Therapeutics in $83.5-million series B financing to advance presbyopia treatments

LENZ Therapeutics raised $83.5-million in an oversubscribed Series B financing. New investor, Sectoral Asset Management, led the financing and was joined by Alpha Wave Ventures and Point 72, as well as existing...

March 7, 2023

Developments

LENZ Therapeutics posts positive Phase 2 presbyopia treatment data

Closely-held LENZ Therapeutics reported positive topline results from its Phase 2 INSIGHT clinical trial of two investigational formulations of aceclidine to treat presbyopia, or farsightedness. Both LNZ100 (aceclidine)...

October 18, 2022

Developments

LENZ Therapeutics and JIXING in exclusive greater China license agreement

Closely-held LENZ Therapeutics entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment...

April 13, 2022

Feature

LENZ Therapeutics readies pivotal trial of aceclidine to treat presbyopia

With a new, experienced management team and a $47-million series A financing in place, closely-held LENZ Therapeutics is gearing up for a pivotal trial of its aceclidine once-daily eye drop to treat presbyopia, the...

July 27, 2021

Developments

Versant, RA Capital launch LENZ Therapeutics in $47-million series A

A $47-million series A financing from Versant Ventures and RA Capital Management launched LENZ Therapeutics, with a lead late-stage clinical program for presbyopia. Proceeds from the financing will be used to progress...

June 17, 2021

Developments

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Humanigen (NASDAQ:HGEN) reported that the National Institutes of Health (NIH) has dosed the first hospitalized COVID-19 patient with lenzilumab. Lenzilumab is an antibody that targets granulocyte-macrophage colony...

October 29, 2020

Tag - LENZ Therapeutics

LENZ Therapeutics, Graphite Bio in merger accord

LENZ partner cleared for Phase 3 presbyopia trial in China

LENZ Therapeutics in $83.5-million series B financing to advance presbyopia treatments

LENZ Therapeutics posts positive Phase 2 presbyopia treatment data

LENZ Therapeutics and JIXING in exclusive greater China license agreement

LENZ Therapeutics readies pivotal trial of aceclidine to treat presbyopia

Versant, RA Capital launch LENZ Therapeutics in $47-million series A

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

General

More